Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

BACKGROUND: The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors. CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Debra M, Jesson, Michael I, Li, Xiong, Elrick, Mollisa M, Funckes-Shippy, Christie L, Warner, James D, Gross, Cindy J, Dowty, Martin E, Ramaiah, Shashi K, Hirsch, Jeffrey L, Saabye, Matthew J, Barks, Jennifer L, Kishore, Nandini, Morris, Dale L
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928212/
https://www.ncbi.nlm.nih.gov/pubmed/20701804
http://dx.doi.org/10.1186/1476-9255-7-41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928212/
https://www.ncbi.nlm.nih.gov/pubmed/20701804
http://dx.doi.org/10.1186/1476-9255-7-41

Ejemplares similares